Safety, tolerability and pharmacokinetics of AFN–1252 administered as immediate release tablets in healthy subjects

AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects

(2013) Nachum Kaplan et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Activity of AFN-1252, a novel FabI inhibitor, againstStaphylococcus aureusin anin vitropharmacodynamic model simulating human pharmacokinetics

(2013) Brian T Tsuji et al.   JOURNAL OF CHEMOTHERAPY

In vitroactivity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics

(2013) Nachum Kaplan et al.   JOURNAL OF CHEMOTHERAPY

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model

(2013) Mary A Banevicius et al.   JOURNAL OF CHEMOTHERAPY

Mode of Action,In VitroActivity, andIn VivoEfficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor

(2012) Nachum Kaplan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Staphylococcus aureus FabI: Inhibition, Substrate Recognition, and Potential Implications for In Vivo Essentiality

(2012) Johannes Schiebel et al.   STRUCTURE

Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors

(2011) J. B. Parsons et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity

(2009) J. A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway

(2008) Hao Lu et al.   ACCOUNTS OF CHEMICAL RESEARCH